The industry could be getting much more out of digital endpoints

Digital endpoints promise to address some of the biggest challenges in clinical trial design and pipeline strategy. So far, however, companies have adopted digital endpoints sparingly, limiting use to a small set of internal decision-making situations, while the endpoints have yet to move the needle in drug approvals. 

There’s more to be gained from digital endpoints, both through broader use as secondary and exploratory endpoints in indications outside of neurology, where the tools’ use is more advanced, and through use as primary endpoints that can support regulatory approvals...